Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
If Big Ben fractured the UK wouldn’t stop talking about it, but in a survey of UK women aged 60 and over, 81% had not discussed their risk of #fragilityfractures with their healthcare professional. Learn more at:https://t.co/Z9ykiMiFqc #WorldOsteoporosisD
— UCB News (@ucb_news) 17.10.2018 -
Did you know that UCB and Amgen collaborated with NASA a few years ago? #UCB90 #Innovation ????️????️ Watch one of our scientists, Alistair Henry, explain the process and what it means for treating cosmonauts’ osteoporosis: https://t.co/FzyfgXTAw4 https:
— UCB News (@ucb_news) 17.10.2018 -
Great to see some of our exciting new research published! https://t.co/OiyO2iil6Z
— UCB News (@ucb_news) 16.10.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
